Home > News > Latest News

Latest News

2010
	Update re Scheme of Arrangement - 28 May 2010 Full Release
	Update re: Scheme timetable - 27 May 2010 Full Release
	Update re Scheme of Arrangement - 27 May 2010 Full Release
	Update re. Scheme of Arrangement - 26 May 2010 Full Release
	Update re. Scheme of Arrangement - 26 May 2010 Full Release
	Update regarding Scheme timetable, listing of GenMark on NASDAQ and GenMark Fundraising - 17 May 2010 Full Release
	Scheme of Arrangement update: results of Osmetech Shareholder Meetings - 28 April 2010 Full Release
	Osmetech plc Receives 510(k) Clearance for the eSensor® Thrombophilia Risk Test - 26 April 2010 Full Release
	Adjournment of Osmetech Shareholder Meetings - 20 April 2010 Full Release
	Proposed adjournment of Osmetech Shareholder Meetings - 19 April 2010 Full Release
	Director exercise of options and Total Voting Rights - 1 April 2010 Full Release
	Posting of scheme document - 31 March 2010 Press Release Scheme document Court meeting proxy General meeting proxy
	Proposed change of Group structure, listing and fundraising on the NASDAQ Global Market and cancellation of AIM trading facility - 19 March 2010 Full Release
	Osmetech plc preliminary results for the 12 months ended 31 December 2009 - 19 March 2010 Full Release
	Total Voting Rights and Share Capital - 15 February 2010 Full Release
	Disclosure of Significant Shareholdings - 20 January 2010 Full Release

2009
	Disclosure of Significant Shareholdings - 30 December 2009 Full Release
	Disclosure of Significant Shareholdings - 24 December 2009 Full Release
	Grant of Warrants and Share Options to Directors - 24 December 2009 Full Release
	Director/PDMR Shareholding - 24 December 2009 Full Release
	Result of GM - 21 December 2009 Full Release
	Osmetech Names John Bellano Sr. Vice President Commercial Operations - 9 December 2009 Full Release
	Proposed Placing of 479,800,841 New Ordinary Shares - 1 December 2009 Full Release
	Change in Details of a Director - 24 November 2009 Full Release
	Grant of Warrants and Share Options to Directors - 8 October 2009 Full Release
	Osmetech and Fisher Agree to Terminate US Distribution Agreement - 24 September 2009 Full Release
	Disclosure of Significant Shareholdings - 24 September 2009 Full Release
	Interim results for the 6 months ended 30 June 2009 - 17 September 2009 Full Release
	Disclosure of Significant Shareholdings - 7 September 2009 Full Release
	Board Changes - 1 September 2009 Full Release
	Osmetech a Finalist for 2009 ABBY Award - 25 August 2009 Full Release
	Disclosure of Significant Shareholdings - 17 August 2009 Full Release
	Osmetech’s eSensor XT-8 System wins ‘R&D 100 Award’ - 30 July 2009 Full Release
	Disclosure of Significant Shareholdings - 20 July 2009 Full Release
	Board Change - 17 July 2009 Full Release
	Disclosure of Significant Shareholdings - 14 July 2009 Full Release
	FDA clears Osmetech’s Cystic Fibrosis Genotyping Test - 9 July 2009 Full Release
	Disclosure of Significant Shareholdings - 1 July 2009 Full Release
	Christopher Gleeson Appointed Chairman - 1 July 2009 Full Release
	£5.5m placing of new ordinary shares - 25 June 2009 Full Release
	Osmetech’s exclusive Warfarin CYP4F2 biomarker included in leading warfarindosing.org algorithm - 8 June 2009 Full Release
	Disclosure of Significant Shareholdings - 3 June 2009 Full Release
	Disclosure of Significant Shareholdings - 26 May 2009 Full Release
	Disclosure of Significant Shareholdings - 22 May 2009 Full Release
	Disclosure of Significant Shareholdings - 18 May 2009 Full Release
	Osmetech’s eSensor XT-8 platform wins Medical Design Excellence Award - 14 May 2009 Full Release
	Osmetech chosen as principal supplier for a major clinical trial - 12 May 2009 Full Release
	Osmetech submits swine flu test to the FDA - 11 May 2009 Full Release
	Results of AGM - 5 May 2009 Full Release
	Osmetech and Fisher HealthCare sign U.S. distribution agreement - 1 April 2009 Full Release
	Osmetech plc preliminary results for the 12 months ended 31 December 2008 - 1 April 2009 Full Release
	Disclosure of Significant Shareholdings - 23 January 2009 Full Release
	Disclosure of Significant Shareholdings - 8 January 2009 Full Release
	Extended warfarin sensitivity test submitted for FDA approval - 6 January 2009 Full Release
	Disclosure of Significant Shareholdings - 5 January 2009 Full Release

2008
	Changes in Board - 31 December 2008 Full Release
	Result of EGM - 22 December 2008 Full Release
	Disclosure of Significant Shareholdings - 17 December 2008 Full Release
	Disclosure of Significant Shareholdings - 15 December 2008 Full Release
	Disclosure of Significant Shareholdings - 10 December 2008 Full Release
	PROPOSED PLACING OF £6.9 MILLION - 4 December 2008 Full Release
	Clinical trials commence for extended warfarin sensitivity test - 10 November 2008 Full Release
	CYP450 2C9 test launch - 4 November 2008 Full Release
	Warfarin Sensitivity study results Update on proposed issue of American Depositary Shares - 31 October 2008 Full Release
	RESULTS OF EXTRAORDINARY GENERAL MEETING - 1 October 2008 Full Release
	Interim results for the 6 months ended 30 June 2008 - 25 September 2008 Full Release
	Osmetech and QIAGEN sign development and supply agreement for QIAplex-based respiratory viral molecular test - 22 September 2008 Full Release
	SEC Registration Statement F-1 - 12 September 2008 Full Release
	Proposed issue of American Depositary Shares and new Ordinary Shares and proposed listing of American Depositary Shares on NASDAQ Global Market - 12 September 2008 Full Release Full Circular
	Board Changes - 12 August 2008 Full Release
	Osmetech Says FDA Clearance of Its Warfarin Test Will Help Expand Menu, Installed Base - 22 July 2008 Full Release
	Osmetech announces first shipments of new eSensor® XT-8 platform and Warfarin Sensitivity Test - 30 July 2008 Full Release
	FDA clears Osmetech’s Warfarin Sensitivity Test and new eSensor® XT-8 platform - 21 July 2008 Full Release
	Change of Adviser - 21 July 2008 Full Release
	Results of AGM - 14 May 2008 Full Release
	Osmetech plc preliminary results for the 12 months ended 31 December 2007 - 28 March 2008 Full Release
	Osmetech licenses Roche polymerase technology - 12 March 2008 Full Release
	Marshfield Clinic Discovers Gene Variant Which Will Significantly Enhance the Accuracy of Molecular Tests for Warfarin Metabolism - 12 February 2008 Full Release
	Disclosure of Significant Shareholdings - 11 January 2008 Full Release
	Warfarin test submitted for FDA approval - 7 January 2008 Full Release

2007
	Disclosure of significant shareholding -12 December 2007 Full Release
	Disclosure of significant shareholding - 26 November 2007 Full Release
	Disclosure of significant shareholding - 19 November 2007 Full Release
	Disclosure of significant shareholding - 12 November 2007 Full Release
	Commencement of clinical trials for warfarin - 12 November 2007 Full Release
	Osmetech Licenses Warfarin Biomarker from Marshfield Clinic - 2 November 2007 Full Release
	Disclosure of Significant Shareholdings - 8 November 2007 Full Release
	Disclosure of Significant Shareholdings - 7 November 2007 Full Release
	Disclosure of Significant Shareholdings - 22 October 2007 Full Release
	Osmetech To Be Awarded New Electrochemical Detection Patents - 4 October 2007 Full Release
	Disclosure of Significant Shareholdings - 3 October 2007 Full Release
	Disclosure of Significant Shareholdings - 27 September 2007 Full Release
	Interim Results for the 6 months to 30 June 2007 - 27 September 2007 Full Release
	U.S. Food and Drug Administration (“FDA“) update labelling for warfarin - 17 August 2007 Full Release
	Osmetech licenses SAM technology to Minerva Biotechnologies - 18 June 2007 Full Release
	Osmetech licenses Roche Hot Start Polymerase Technology - 5 June 2007 Full Release
	Osmetech plc – AGM Statement - 3 May 2007 Full Release
	Annual Report and Accounts 2006 - 3 April 2007 Full Release
	Preliminary Results for the year ended 31 December 2006 - 20 March 2007 Full Release
	Osmetech plc - Cancellation of Warrants - 20 March 2007 Full Release
	Osmetech licenses VKOR pharmacogenetic marker for warfarin dosage management from University of Washington - 09 March 2007 Full Release
	Appointment of Director - 14 February 2007 Full Release
	Completion of US$ 44.9 million sale of Critical Care Division to IDEXX - 01 February 2007 Full Release
	Molecular Diagnostics supply agreement - 16 January 2007 Full Release
	Osmetech and EPIDAUROS establish strategic partnership to develop pharmaceutical companion diagnostics and novel molecular diagnostic products - 09 January 2007 Full Release

2006
	Disposal of Critical Care Division - 18 December 2006 Full Release
	Osmetech increases patent holdings - 15 November 2006 Full Release
	Osmetech licenses pharmacogenetic marker for P450-CYP2D6 from EPIDAUROS - 16 October 2006 Full Release
	Osmetech licenses self-assembling monolayer (SAM) nanotechnology to Evanston, Illinois-based Ohmx Corporation - 10 October 2006 Full Release
	Interim Results for the 6 months to 30 June 2006 - 13 September 2006 Full Release
	Trading Update - 10 July 2006 Full Release
	Trading update and Placing of 71,000,000 new ordinary shares - 16 June 2006 Full Release Full Circular
	AGM Statement - 3 May 2006 Full Release
	Osmetech Annual Report & Accounts for the 8 months ended 31 December 2005 - 3 April 2006 Investors - Company Reports
	Launch of eSensor Cystic Fibrosis Carrier Detection System - 28 March 2006 Full Release
	Preliminary Results for the 8 months to 31st December 2005 - 21 March 2006 Investors - Company Reports
	FDA clearance for cystic fibrosis molecular diagnostics test - 24 January 2006 Full Release
	Appointment of Nominated Advisor and Broker - 20 January 2006 Full Release
	Trading Update - 19 January 2006 Full Release

2005
	Osmetech Annual Report and Accounts for 2005 - 8 September 2005 Investors - Company Reports
	Preliminary Results for the 12 months to 30th April 2005 - 2 September 2005 Full Release
	Osmetech appoints head of newly acquired CMS - 4 August 2005 Full Release
	New OPTI products update - 1 August 2005 Full Release
	CMS Cystic Fibrosis clinical research poster - 14 July 2005 Full Document (pdf)
	Proposed acquisition of Clinical Micro Sensors, Inc. ("CMS") from Motorola, Inc., and Placing - 1 July 2005 Full Release Full Circular
	Vial Technology License to Roche Diagnostics - 27 April 2005 Full Release
	Interim Report for the 6 months to 31st October 2004 - 27 January 2005 Full Release